Will drug resistance against dolutegravir in initial therapy ever occur?

Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) and INSTIs are the latest class of potent anti-HIV drugs. Compared to the first generation INSTIs, raltegravir, and elvitegravir, DTG shows a limited cross-resistance profile. More interestingly, clinical resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wainberg, Mark A., Han, Ying-Shan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413831/
https://www.ncbi.nlm.nih.gov/pubmed/25972810
http://dx.doi.org/10.3389/fphar.2015.00090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413831/
https://www.ncbi.nlm.nih.gov/pubmed/25972810
http://dx.doi.org/10.3389/fphar.2015.00090

Ejemplares similares